L-Arginine therapy in cardiovascular pathologies: Beneficial or dangerous?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 1, 2008, Pages 55-61

  Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Asymmetric dimethylarginine; Endothelium; Nitric oxide; Nitric oxide synthase

Indexed keywords

ARGININE; DIMETHYLARGININASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO;

AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MORTALITY; NUTRITION; PROTECTION; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ARGININE; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 37349064459     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282f2b0c3     Document Type: Review

References (62)

1. Rose WC. The nutritional significance of the amino acids. Physiol Rev 1938; 18:109-136.
2. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336:1-17.
3. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
4. Förstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23:1121-1131.
5. Förstermann U, Boissel JP, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12:773-790.
6. G-hydroxy- L-arginine by cultured endothelial cells. Proc Natl Acad Sci U S A 1991; 88:11172-11176.
7. Bohme GA, Bon C, Lemaire M, et al. Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci U S A 1993; 90:9191-9194.
8. Paakkari I, Lindsberg P. Nitric oxide in the central nervous system. Ann Med 1995; 27:369-377.
9. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127:1-11.
10. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48:489-509.
11. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol 2004; 20 (Suppl B):7B-15B.
12. Li XA, Everson W, Smart EJ. Nitric oxide, caveolae, and vascular pathology. Cardiovasc Toxicol 2006; 6:1-13.
13. Napoli C, De Nigris F, Williams-Ignarro S, et al. Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006; 15:265-279. This review summarizes currently available experimental data on the pathophysiological role of NO in atherosclerosis.
14. Kilbourn R. The discovery of nitric oxide as a key mediator in septic shock. Sepsis 1998; 1:85-91.
15. Silk DB, Grimble GK, Rees RG. Protein digestion and amino acid and peptide absorption. Proc Nutr Soc 1985; 44:63-72.
16. Souci SW, Fachmann W, Kraut H. Food composition and nutrition tables. 5th ed. Stuttgart: Medpharm; 1994.
17. Möller P, Bergström J, Eriksson S, et al. Effect of aging on free amino acids and electrolytes in leg skeletal muscle. Clin Sci 1979; 56:427-432.
18. Möller P, Alvestrand A, Bergström J, et al. Electrolytes and free amino acids in leg skeletal muscle of young and elderly women. Gerontology 1983; 29:1-8.
19. G-monomethy-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 1995; 269:C750-C756.
20. Böger RH, Sydow K, Borlak J, et al. LDL Cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99-105.
21. Schmidt HH, Nau H, Wittfoht W, et al. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 1988; 154:213-216.
22. Castillo L, de Rojas T, Chapman TE, et al. Splanchnic metabolism of dietary arginine in relation to nitric oxide synthesis in normal adult man. Proc Natl Acad Sci U S A 1993; 90:193-197.
23. 15N-labeled nitrate by gas chromatographymass spectrometry. Nitric Oxide 2004; 11:1-8.
24. Merimee TJ, Rabinovitz D, Riggs L, et al. Plasma growth hormone after arginine injection. N Engl J Med 1967; 276:434-439.
25. Bode-Böger SM, Böger RH, Creutzig A, et al. L-Arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy volunteers. Clin Sci 1994; 87:303-310.
26. Bode-Böger SM, Böger RH, Alfke H, et al. L-Arginine induces NO-dependent vasodilation in patients with critical limb ischemia - a randomized, controlled study. Circulation 1996; 93:85-90.
27. Bode-Böger SM, Böger RH, Galland A, et al. Pharmacokinetic-pharmacodynamic relationship of the effects of intravenous and oral L-arginine on nitric oxide formation and peripheral haemodynamics in healthy human subjects. Br J Clin Pharmacol 1998; 46:489-497.
28. Böger RH, Bode-Böger SM, Heinzel D, et al. Differential systemic and pulmonary haemodynamic effects of L-arginine in patients with coronary heart disease and primary pulmonary hypertension. Int J Clin Pharmacol Ther 1996; 34:323-328.
29. Bode-Böger SM, Böger RH, Löffler M, et al. L-arginine stimulates NO-dependent vasodilation in humans - effect of somatostatin pretreatment. J Invest Med 1999; 47:43-50.
30. Giugliano D, Marfella R, Verazzo G, et al. The vascular effects of L-arginine in humans. J Clin Invest 1997; 99:433-438.
31. Calver A, Collier J, Leone A, et al. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7:193-194.
32. Bode-Böger SM, Muke J, Surdacki A, et al. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med 2003; 8:77-81.
33. Jeserich M, Münzel T, Just H, Drexler H. Reduced plasma L-arginine in hypercholesterolaemia. Lancet 1992; 339:561.
34. Morris SM Jr. Enzymes of arginine metabolism. J Nutr 2004; 134:2743S-2747S.
35. Bachetti T, Comini L, Francolini G, et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004; 37:515-523.
36. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; 108:2000-2006.
37. Xu W, Kaneko FT, Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004; 18:1746-1748.
38. Zhang C, Hein TW, Wang W, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004; 44:935-943.
39. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287:L60-L68.
40. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59:824-833.
41. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38:126-136. This review gives an overview of the biochemistry, physiology and clinical data on ADMA, and its role as a cardiovascular risk marker.
42. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005; 10:14-23.
43. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546-1550.
44. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80:331-333.
45. Bednarz B, Wolk R, Chamiec T, et al. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int J Cardiol 2000; 75:205-210.
46. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93:2135-2141.
47. Bednarz B, Jaxa-Chamiec T, Gebalska J, et al. L-Arginine supplementation prolongs exercise capacity in congestive heart failure. Kardiol Pol 2004;60:348-353.
48. Blum A, Hathaway L, Mincemoyer R, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101:2160-2164.
49. Walker HA, McGing E, Fisher I, et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001; 38:499-505.
50. Dudek D, Legutko J, Heba G, et al. L-Arginine supplementation does not inhibit neointimal formation after coronary stenting in human beings: an intravascular ultrasound study. Am Heart J 2004; 147:e12.
51. Bednarz B, Jaxa-Chamiec T, Maciejewski P, et al. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol 2005; 62:421-427.
52. Schulman SP, Becker LC, Kass DA, et al. L-Arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295:58-64. This paper reports the data from a large, placebo-controlled clinical trial on the effects of L-arginine supplementation in patients after myocardial infarction. The study was terminated early due to safety concerns.
53. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006; 48:602-608.
54. Abumrad NN, Barbul A. Arginine therapy for acute myocardial infarction [letter]. JAMA 2006; 295:2138-2139.
55. Böger RH. Letter to the editor re: JAMA article on L-arginine therapy in acute myocardial infarction. Altern Med Rev 2006; 11:91-92.
56. Wilson AM, Harada R, Nair N, et al. L-Arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007; 116:188-195. This paper reports the data of a long-term supplementation study with L-arginine vs. placebo in patients with peripheral arterial disease. L-Arginine improved vascular function and walking distance significantly less than placebo in this unselected population.
57. Lee J, Ryu H, Ferrante RJ, et al. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A 2003; 100:4843-4848.
58. Morris SM Jr. Arginine metabolism in vascular biology and disease. Vasc Med 2005; 10 (Suppl 1):S83-S87.
59. Maas R. Pharmacotherapeutic interventions and their influence on ADMA levels. Vasc Med 2005; 10 (Suppl 1):S49-S57.
60. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of ADMA using a novel ELISA assay. Clin Chem Lab Med 2004; 42:1377-1383.
61. Schulze F, Maas R, Freese R, et al. Determination of a reference value for N,N-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005; 35:622-626.
62. Schwedhelm E, Tan-Andresen J, Maas R, et al. LC-tandem MS method for the analysis of asymmetric dimethylarginine (ADMA) in human plasma. Clin Chem 2005; 51:1268-1271.